EXHIBIT 10.4
FOR IMMEDIATE RELEASE
Contacts: Urologix:
Fred B. Parks, Chairman and CEO
Todd E. Paulson, Chief Financial Officer
Brooks West, Director, Marketing & Business Development
(763) 475-1400
Urologix Announces Agreement for
the Development of Real-Time Imaging System
Minneapolis - August 2, 2005 - Urologix(R), Inc. (NASDAQ:ULGX),
has
entered into a co-development agreement
with ProUroCare Medical, Inc. (OTC BB:
PRRC.OB), and Rensselaer Polytechnic
Institute to develop a real-time
temperature imaging system,
ProUroVision(TM), to be utilized with Urologix'
Cooled ThermoTherapy(TM) treatment of
benign prostatic hyperplasia (BPH) as well
as potential new indications.
Cooled
ThermoTherapy is a single, minimally invasive in-office
treatment
that uses targeted microwave energy
combined with a unique cooling mechanism to
provide safe, effective and lasting relief
from BPH symptoms. BPH, also known as
enlarged prostate disease, is a
non-cancerous condition that can make urination
difficult or painful and is common in men
over the age of 50.
"We look
forward to working with the researchers at Rensselaer
Polytechnic
Institute and the scientific and
engineering team at ProUroCare," said David
Montecalvo, Urologix vice president of
product development and operations. "If
successful, we will be able to provide
accurate discrete temperature
measurements at multiple points in the
prostate. This information will allow our
treating physicians to view an image of the
patients' prostate during the
procedure, showing the heating effect and
associated tissue necrosis resulting
from our Cooled ThermoTherapy treatment in
real-time."
Maury
Taylor, ProUroCare chairman and chief executive officer,
commented,
"We are ex
